Author: paroukatos

20 Aug Blood Pressure Reduction Is Not the Only Determinantof Outcome

Posted at 10:24h in Μελέτες by paroukatos

Peter S. Sever, FRCP; Neil R. Poulter, FRCP Whether certain classes of antihypertensive drugs confer benefits beyond those associated with lowering blood pressure remains a highly controversial issue. Data from several meta-analyses have been used to support the notion that most, if not all, of the...

20 Aug Is New-Onset Diabetes of Clinical Significance in Treated Hypertensive Patients?—Con

Posted at 10:22h in Μελέτες by paroukatos

Marvin Moser, MD There is little doubt that diabetes is more common in hypertensive than normotensive individuals. There are also some data suggesting that the use of certain antihypertensive agents, i.e., diuretics and more specifically some blockers will increase the occurrence of new onset diabetes (NOD)...

20 Aug Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo

Posted at 10:22h in Μελέτες by paroukatos

Athanasios J. Manolisa, John L. Reidb, Dick de Zeeuwc, Michael B. Murphyd, Elke Seewaldt-Beckere and Ju¨ rgen Ko¨ sterf on behalf of the ARAMIS Study Group Objective: To identify telmisartan doses that are more effective than placebo and non-inferior to hydrochlorothiazide (HCTZ) 12.5 mg, and are well...

20 Aug More Confusing Messages From the Hypertension Treatment Trials

Posted at 10:21h in Μελέτες by paroukatos

Marvin Moser, MD Editor in Chief Over the past 5 years, numerous hypertension treatment trials have been completed and reported.1-8 A majority of these trials were initiated to distinguish one therapy from another in reducing cardiovascular (CV) events. Some were blinded and appropriately randomized prospective trials;...

20 Aug CAMELOT: Study Design

Posted at 10:20h in Μελέτες by paroukatos

A Morbidity and Mortality Study CAMELOT: Primary End Point Time to first composite major CV event (MACE): CV death Nonfatal MI Resuscitated cardiac arrest Need for coronary revascularization Hospitalization for: Angina CHF PVD procedure Stoke (fatal or nonfatal) or TIA PVD (new diagnosis) CAMELOT: Secondary End Points ...

20 Aug INternational VErapamil SR and Trandolapril STudy

Posted at 10:19h in Μελέτες by paroukatos

Principal Investigator: Carl J. Pepine, MD Division of Cardiovascular Medicine University of Florida College of Medicine Gainesville, Florida USA What Is INVEST? INVEST (the INternational VErapamil SR and Trandolapril STudy) is the first randomized, prospective trial to exclusively study patients with hypertension and coronary artery disease (CAD). INVEST is also the first...

20 Aug ACTION

Posted at 10:19h in Μελέτες by paroukatos

Ο σχεδιασμός της μελέτης Για πρώτη φορά μέχρι σήμερα, σχεδιάστηκε μία τέτοιου μεγέθους, τυχαιοποιημένη και ελεγχόμενη με τη χορήγηση εικονικού φαρμάκου μελέτη, προκειμένου να αξιολογήσει τα κλινικά αποτελέσματα της χορήγησης ενός αντιστηθαγχικού φαρμάκου σε ασθενείς με συμπτωματική σταθερή στηθάγχη. Σχεδιάστηκε με σκοπό να αξιολογήσει την...

20 Aug The angiotensin II receptor antagonist telmisartan reduces rinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.

Posted at 10:18h in Φάρμακα by paroukatos

Liffert Vogta, Gerjan Navisa, Ju¨ rgen Ko¨ sterb, Athanasios J. Manolisc, John L. Reidd, Dick de Zeeuwa and on behalf of the Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group Objective: To examine the effect of telmisartan or hydrochlorothiazide on the control...

20 Aug Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

Posted at 10:17h in Φάρμακα by paroukatos

Ralf A. Benndorf4, Tanja Rudolph, Daniel Appel, Edzard Schwedhelm, Renke Maas, Friedrich Schulze, Elisabeth Silberhorn, Rainer H. Bfger Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, University Hospital Hamburg-Eppendorf, D-20246 Hamburg, Germany Received 18 January 2006; accepted 18 April 2006 Abstract Hypertension is a...

20 Aug Telmisartan in patients with mild/moderate hypertension and chronic kidney disease

Posted at 10:16h in Φάρμακα by paroukatos

A.M. Sharma1, A. Hollander2 and J. Köster3 1University Clinic Benjamin Franklin, Freie Universität, Berlin, 2Bosch Medicentrum, Den Bosch, The Netherlands, and 3Boehringer Ingelheim Pharma KG, Ingelheim, Germany, on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group Abstract. Aims: This study as sessed the...